Background. The induction of neutralizing antibodies against conserved regions of the human immunodeficiency virus type 1 (HIV-1) envelope protein is a major goal of vaccine strategies. We previously identified 3S, a critical conserved motif of gp41 that induces the NKp44L ligand of an activating NK receptor. In vivo, anti-3S antibodies protect against the natural killer (NK) cell-mediated CD4 depletion that occurs without efficient viral neutralization.
that gp41 is a target-rich environment with numerous potential sites for therapeutic intervention [13] . We have shown that the 3S motif, located between residues 618-623 in the gp41 loop region (according to the position of gp160 of the BRU HIV-1 strain), is remarkably conserved and specific to HIV-1 strains. These features indicate that this motif is probably important to the conformation and/or the functionality of the virus [14] . This mechanism has been thoroughly investigated at the cellular level to reveal that the 3S motif binds to gC1qR, the receptor for the globular domain of C1q complement factor [15] . This interaction induces NKp44L, the cellular ligand of an activating natural killer (NK) receptor (NKp44), rendering CD4 + T cells sensitive to NK lysis. NKp44L expression is strongly correlated with both the decline of CD4 cell count, and other side effects linked to the pathogenicity (ie, T-cell activation, inflammation, and apoptosis) both ex vivo in HIV-infected patients, and in vivo in macaques immunized with the 3S motif [14, 16] .
The CD4 + T-cell loss observed during the chronic phase of HIV-1 infection is principally due to the death of uninfected bystander cells [17, 18] . We found that Nef, one of the principal effector proteins aiding HIV immune evasion, mediates intracellular retention of NKp44L in HIV-infected CD4 + T cells [19, 20] .
These results suggest that HIV-1 uses NK cells to disarm the host immune system by selectively triggering the death of uninfected CD4 + T cells.
We show here, for the first time, that specific substitutions in the 3S motif elicit broadly neutralizing activity against HIV-1. This finding provides a rational basis for the generation of NAbs and for designing an HIV vaccine that both elicits these NAbs and protects against CD4 depletion.
MATERIALS AND METHODS

Human Plasma Samples From HIV-Infected Patients
Plasmas were collected from 106 HIV-1-infected volunteers at the Pitié-Salpêtrière hospital (Paris, France). Written informed consent was obtained by study participants. Eligible participants were aged ≥18 years, HIV-1 infected for at least 2 years prior the day of the screening, and undergoing highly active antiretroviral therapy. Plasma samples were collected as previously described [21] , and then heat-inactivated at 55°C for 45 minutes prior to neutralization assays.
Virus Preparation
Mutants were prepared from plasmid pNL4.3 with the QuickChange II XL Site-directed mutagenesis kit (Stratagene), and then verified by DNA sequencing. Wild-type (WT) and alaninemutated 3S pNL4.3 plasmids were transfected by lipofectamine (Invitrogen) into 293T cells in Optima medium. Cell-free supernatant was harvested 48 hours after transfection, and the concentration of p24 was measured with the Vidas Ag p24 II kit (bioMérieux). Virus supernatants were frozen and stored at −80°C.
Peptides, Antibodies, and Enzyme-Linked Immunosorbent Assay
Purified unconjugated and keyhole limpet hemocyanin (KLH)-conjugated WT [14] , and alanine-mutated 3S synthetic peptides ( purity of each peptide >95%) were purchased from Covalabs (Villeurbanne, France). Sequence of peptides are listed in Supplementary Table 1 . Six Balb/c 7-week-old female mice received 4 subcutaneous injections with 40 μg of KLH-linked peptide in incomplete Freund adjuvant, 14 days apart. Sera were collected at day 63. The sera were titrated by enzyme-linked immunosorbent assay (ELISA), as described previously [21] .
Infection Assay
Ten million cells were incubated with 100 ng of p24 antigen equivalents, for 17 hours ( purified primary activated CD4 + T cells from different healthy donors) or 2 hours (MT-2 and Jurkat cells) at 37°C. Virus production was monitored every 2 days after infection by measuring the p24 concentration. Syncytium formation on infected MT2 cells was assessed after 96 hours by standard phase contrast microscopy.
Single-Round HIV-1 Infectivity Assay
HeLa P4C5 cells [22] were seeded 1 day before and infected with 4 ng p24/mL of WT or mutated NL4.3 viruses. At 48 hours after infection, the β-galactosidase activity was measured in HeLa-P4C5 cell lysates with the CPRG Beta-Galactosidase Kit (OZ Biosciences).
Quantitative ELISA for gp41 in HIV Particles
Virus-containing culture of transfected 293T cell supernatants were harvested and clarified by filtration through a 0.45-μm filter. Virus samples were treated as described [23] , and then assayed for p24 (Vidas Ag p24 II kit) and gp41 (gp41 Immunodiag Inc) ELISA. The relative level of particle-associated gp41 was calculated as the ratio of the gp41 and p24 concentrations.
Neutralization Assays
Polyclonal immunoglobulin G fractions from mouse antisera were isolated with the Nab Protein A/G Spin kit and then desalted with Zeba spin desalting columns (both from Thermo Scientific). Immunoglobulin fractions were concentrated with Centricon Centrifugal Filter Units (Millipore) and then quantified with the BCA protein assay kit (Thermo Scientific). Purified immunoglobulins were tested at starting concentrations of 20 μg/mL, followed by five 2-fold dilutions.
Human Abs were purified by immunoprecipitation with heat-inactivated plasma from HIV-infected patients; the Pierce Direct IP kit was used, and synthetic peptides (WT and W614A) were directly immobilized onto an amine-reactive agarose support. Purified Abs were dialyzed against phosphate-buffered saline (Silde-A-Lyser Dialysis cassette, Pierce), quantified, and then tested at starting concentrations of 2 μg/mL, followed by five 2-fold dilutions.
Neutralization of the purified Abs was tested, as described [24, 25] (1) to compare potency (concentrations required to achieve 50% [IC 50 ] inhibition) of Abs in the presence of 200 median tissue culture infective dose (TCID 50 ) with a standard CD4 + T-cell p24 assay, and (2) to determine the ability of Abs to inhibit HIV-1 entry using both HeLa-P4C5 and Tzm-bl reporter cells. At 48 hours after infection, β-galactosidase activity in HeLa-P4C5 lysates was measured as well as luciferase activity in TZM-bl lysates with either the Britelite Plus Reagent (Perkin Elmer) or the Brite-glow reagent (Promega). A cutoff value of 2.5 times background was applied to determine positive values.
Flow Cytometry
Fluorescence-activated cell sorting analysis was performed on purified CD4 + T cells as described [14] , in the presence of Cr-release assay, as described [14] .
RESULTS
Effect of Mutations of the 3S Motif on Infection of CD4 + T Cells
To examine the role of the 3S motif in the virus life cycle, single-point substitutions were individually introduced at residues between positions S613 and S618 in the 3S motif from the NL4.3 HIV-1 strain. Figure 1A shows that the effects of these substitutions were ranged from the near-total abolition of virus production (for W614A and S618A) to nil for viruses expressing the WT virus. This finding was confirmed by the modulation of their inability to form syncytia ( Figure 1B ). Kinetic studies of infection show that the replication was undetectable with W614A and S618 mutated viruses, at every time period compared to the WT virus in purified CD4 + T ( Figure 1C ) and Jurkat cells (data not shown). These data are consistent with the level of infectivity detected in HeLa P4C5 cells ( Figure 1D ). Of note, the amount of gp41 incorporated in the viral particles remains similar in all harvested WT and mutant particles ( Figure 1E ).
Point Mutations in the 3S Motif Abolish NKp44L Expression
We and other researchers have previously shown that HIV-1 infection induces expression of some specific ligands for NK receptors, including NKp44L [14, 27] . Figure 2A shows a high percentage of NKp44L + CD4 + T cells after infection with WT virus, but no expression with W614A and S618A mutants ( Figure 2A ). Similar results were obtained with heat-inactivated virus (data not shown) or after stimulation with the corresponding synthetic 3S peptides ( Figure 2B ). These findings indicate that NKp44L cell-surface translocation can be modulated by specific point-mutations in the 3S motif.
Degranulation of NK Cells Was Modulated in the Presence of Autologous CD4 + T Cells Infected by 3S Viral Mutants
Because NKp44L expression is modulated on CD4 + T cells after infection with certain 3S viral mutants, we next investigated their sensitivity to NK degranulation. Figure 2C shows that Figure 2D ). Altogether, these results suggest that specific substitutions in the 3S motif have major consequences for modulation of the NK-cell sensitivity of CD4 + target cells.
Elicitation of 3S-like Broadly Neutralizing Antibodies in Mice
We therefore immunized mice with WT and each of mutated 3S peptides to generate specific Abs. All of them showed robust immune responses against their specific 3S sequences on ELISA (data not shown). Consistently with our previous findings [14] , NKp44L expression ( Figure 3A ) and degranulation of NK cells ( Figure 3B ) were strongly inhibited in the presence of Ig from both 3S-WT and mutant-peptide immunized mice, regardless to the position of the substitutions. Similar results were observed with a standard 4-hour chromium assay (Supplementary Figure 1) , suggesting that all immunoglobulins from mutantpeptide immunized mice protect CD4 + T cells against autologous lysis by NKp44 + NK cells.
Furthermore, we determined the capacity of viral neutralization of immunoglobulin from both 3S-WT and mutants on cross-clade HIV-1 strains using different cell-based neutralization assays. Robust and broadly neutralizing activity was only detected with immunoglobulins of 4 mutant-peptide immunized mice against various tier 1 (BRU, NDK, NL4.3) and tier 2 ( JR-CSF, YU-2) HIV-1 clade B strains (Table 1) . More importantly, immunoglobulins from the W614A mutantpeptide immunized mice was able to strongly neutralize all tier 1 and tier 2 HIV-1 strains from the different clades (A, C, and E), in HeLa-P4C5 (Table 1 ) or in TZM-bl (Table 2) assays. As expected [14] , no neutralizing activities were detected with immunoglobulin of WT peptide immunized mice, and in the presence of vesicular stomatis virus (VSV) and ROD HIV-2 strain, demonstrating the specificity of the response (Table 2 ). To further confirm these data, we sought to detect p24 production by purified CD4 + T cells infected with NL4.3 or NDK HIV-1 strains. Figure 3C shows that the p24 production remains undetectable with immunoglobulins from W614A mutant-peptide immunized mice, for a concentration superior to 10 μg/mL immunoglobulins at any time after infection. In contrast, immunoglobulins from S615A, N616A and S618A mutant-peptides immunized mice appeared to only delay p24 production ( Figure 3D ). Together, these data strongly support the conclusion that substitution at the W614 position in the 3S motif elicited a capacity to neutralize cross-clade viruses, notable in its magnitude, breadth, and durability. 
Abs Against the W614A 3S Mutant Eluted From the Plasma of HIV-1 Patients Showed Neutralizing Activity
We next sought to determine efficacy of W614A-3S Abs purified from plasma samples of HIV-1-infected patients. Anti-3S-WT Abs were found in approximately 52% (55/106) of plasma samples from HIV-1-infected patients, with values ranging from 15 AU/mL to 325 AU/mL, with a highly significant with the CD4 count (P < .0001; Spearman test), as described [28] . However, Abs specifically directed against the W614A-mutated 3S motif were only detected in plasma samples of 5 of the 106 patients (4.7%) ( Table 3 ). These specific Abs were immunoglobulin G isotypes (data not shown) and were detected exclusively in patients with high CD4 counts and undetectable viral loads (<20 copies/mL) ( Table 3) ; of note, these Abs were not detectable in the plasma of healthy donors (data not shown).
A neutralizing activity was measured with all of these sera (Table 3) . After their immune-purification against the W614A peptide, these specific immunoglobulins preserved a robust neutralizing activity ( Figure 4A ). Furthermore, a kinetic study showed that p24 production in cell-free supernatant was lower in the presence of purified Abs from HIV-1-infected patients (regardless of the time since infection) than those from controls ( Figure 4B ). Importantly, a cross-reactivity experiment revealed that W614A-purified NAb only react with its corresponding mutant 3S-peptide, but not with WT 3S peptide or other tested peptides (Supplementary Figure 2) .
W614A-purified Abs from most patients were able to neutralize to high titers all or most of tier1 (clade B and C) and tier 2 viruses of clade B (Table 3) . Strikingly, purified Abs from 1 of these 5 patients (number 109) was also reactive against tier2 clade C (PSV-TV1) and clade E (PSV-CM244) viruses. No W614A-purified Abs neutralized HIV-2 ROD or VSV, used as negative controls.
We next looked at the effects of these anti-W614A NAbs on the NKp44L expression and the NK degranulation, when autologous CD4 + T cells were co-cultured with autologous IL-2-activated NK cells. We observed that these NAbs have preserved these activities (NKp44L expression and NK degranulation), at levels similar to those observed in the presence of the control 3S WT Ab ( Figure 4C and 4D) . Similar results were observed with a standard lysis assay (Supplementary Figure 1) . This suggests that W614A-reactive human Abs protect CD4 + T cells against autologous lysis by activated NKp44 + NK cells.
DISCUSSION
In this study, alanine-scanning allowed us to identify a specific position in the 3S motif (W614A) that inhibits HIV entry, elicits neutralizing antibodies, and remains able to counter NK cytotoxicity against CD4 + T cells.
Previous studies have partially characterized the effects on virus entry of single-site mutations in the HIV-1 gp41 loop [29, 30] . Although some of these mutations impaired envelope functions, discrepancies between these results can be attributed to the different assays used to test these functions (eg, cell-cell fusion assays vs virus entry investigations) in association with conformational modifications [29, 31] . Nevertheless, in this study, specific substitutions in the 3S motif-W614A, S615A, N616A, and S618A-were clearly associated with both impaired infectivity and virus entry. This is consistent with the absence of NKp44L induction on CD4 + T cells in the presence of these mutants and with their recognition by autologous activated NK cells. Of note, NKp44L expression was detected after infection with pseudoviruses deficient for the fusion (Env41.2), but not for the CD4 binding (D368R) ( personal communication, J. Blanco, IrsiCaixa-HIV/ACAT, Barcelona, Spain), indicating that the attachment of the 3S motif to the cells occurs after the CD4 interaction but before the fusion event, suggesting that fusogenic and NKp44L activities are independent. Surprisingly, sera from mice immunized with certain mutated 3S peptides acquired neutralizing capacities. However, kinetic studies in CD4 + T cells showed that for most of these mutants, protection was transient and rapidly returned to the level observed with the WT. However, the neutralizing effect of the antimutated W614A Abs remains completely preserved during follow-up. This was reinforced by data from various neutralizing assays and suggests that compared with both the other substitutions and other known NAbs (ie, 2F5), anti-W614A Abs are unparalleled in there magnitude, breadth, and ability to confer their specific effects durably on cross-clade viruses. Although some earlier reports have shown that gp41 changes can partially impair neutralization sensitivity [32] [33] [34] [35] , this is the first study showing that a specific point-substitution within a very highly conserved motif of gp41 induces production of NAbs when the WT motif itself does not, in line with the quasi-absence of neutralizing activity against this gp41 region [36] . This is confirmed by the presence of naturally occurring anti-W614A NAbs in vivo in sera from HIV-1-infected patients. This suggests that conserved epitopes in this unique gp41 region might be immunogenic after specific substitutions, even though the W614A mutation confers relatively ineffectual infectivity in vitro.
The identification by mutation of at least one major position in a highly conserved gp41 motif strongly suggests that the 3S motif plays an important role in generating a high titer of broadly NAb responses. The question naturally arises as to why a region of gp41 that is so heavily guarded and difficult to target by NAbs is a key determinant of potent NAb responses in HIV-infected individuals. The precise mechanism by which a specific alanine substitution in the 3S motif enable the exposure of neutralization epitopes remains unclear; the absence of this region from the crystal structure of the gp41 ectodomain unfortunately impedes a full understanding of the structural changes that contribute to the exposure of key motifs after specific substitutions [12] . However, the absence of cross-reactivity of the anti-W614A-mutated Abs with the 3S WT peptide, as well as ongoing structural modeling study, suggested that the stability of the W614A mutated peptide with the gC1qR is impacted, compared to the 3S WT peptide (personal communication, M. Baaden, Institut Curie, Paris, France). Further studies need, however, to be performed to precisely determine this phenomenon.
Importantly, our data also show that the acquisition of neutralization capacities preserves the unique ability of anti-3S Abs to inhibit NKp44L expression on CD4 + T cells, as previously described for anti-WT-3S Abs, and confirmed in vivo in a simian immunodeficiency virus-infected macaque model [16, 21] . This phenomenon is essential in view of critical importance of CD4 + T-cell preservation in this disease, unfavorable clinical outcomes being correlated with the failure of CD4 recovery in immunological nonresponders [37] . Our data show that the mutation of a specific residue in the 3S motif generate Abs that combine a capacity to neutralize the virus with protection against CD4 depletion. These findings provide a foundation for the rational design of a dual-purpose vaccine to boost both virus cross-clade neutralization and protect from CD4 + T-cell depletion.
